Co-Authors
This is a "connection" page, showing publications co-authored by Paige Wickner and Kimberly Blumenthal.
Connection Strength
3.568
-
Acute Allergic Reactions to mRNA COVID-19 Vaccines. JAMA. 2021 04 20; 325(15):1562-1565.
Score: 0.941
-
Addressing Inpatient Beta-Lactam Allergies: A Multihospital Implementation. J Allergy Clin Immunol Pract. 2017 May - Jun; 5(3):616-625.e7.
Score: 0.715
-
Incidence of Cutaneous Reactions After Messenger RNA COVID-19 Vaccines. JAMA Dermatol. 2021 08 01; 157(8):1000-1002.
Score: 0.240
-
Allergic symptoms after mRNA COVID-19 vaccination and risk of incomplete vaccination. J Allergy Clin Immunol Pract. 2021 08; 9(8):3200-3202.e1.
Score: 0.238
-
COVID-19 Vaccination in Patients with Reported Allergic Reactions: Updated Evidence and Suggested Approach. J Allergy Clin Immunol Pract. 2021 06; 9(6):2135-2138.
Score: 0.235
-
Reply to "PEG skin testing for COVID-19 allergy". J Allergy Clin Immunol Pract. 2021 04; 9(4):1765-1766.
Score: 0.234
-
mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. J Allergy Clin Immunol Pract. 2021 04; 9(4):1423-1437.
Score: 0.230
-
Clinical decision support improved allergy documentation of antibiotic test dose results. J Allergy Clin Immunol Pract. 2019 Nov - Dec; 7(8):2919-2921.
Score: 0.206
-
Tackling inpatient penicillin allergies: Assessing tools for antimicrobial stewardship. J Allergy Clin Immunol. 2017 Jul; 140(1):154-161.e6.
Score: 0.177
-
Adverse and Hypersensitivity Reactions to Prescription Nonsteroidal Anti-Inflammatory Agents in a Large Health Care System. J Allergy Clin Immunol Pract. 2017 May - Jun; 5(3):737-743.e3.
Score: 0.175
-
First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing. J Allergy Clin Immunol Pract. 2021 09; 9(9):3308-3320.e3.
Score: 0.060
-
Reply to "How important is the second dose of the COVID-19 mRNA vaccine?" J Allergy Clin Immunol Pract. 2021 06; 9(6):2537-2539.
Score: 0.059
-
The Importance of a Timely Second Dose of the 2021 COVID-19 mRNA Vaccine Depends on the Protection Afforded by a First Dose and Subsequent Risk of Anaphylaxis. J Allergy Clin Immunol Pract. 2021 07; 9(7):2556-2561.
Score: 0.059